🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Largest study to date reveals detectable naloxone metabolites in patient taking buprenorphine -naloxone combo, questioning the previous claims that naloxone combination is minimal. Its likely that it may contribute to side-effects for some patients, and switching to injectable

Intriguing social media data suggest LSD use may decrease gender dysphoria in some people, as well as precipitate new gender identities or gender questioning in others liebertpub.com/doi/abs/10.108…

Had a nice opportunity to collaborate on this piece exploring safety of ketamine in psychiatry. We discuss lack of a REMS & potential regulatory alternatives and why patients w SUDs should be included in trials to guide real world clinical decision making. jamanetwork.com/journals/jamap…

In ELEKT-D trial, ketamine preferrers had higher chances of ketamine treatment response than ECT preferrers, though treatment preference had no effect on ECT response. Ketamine preferrers receiving ECT were more likely to report AEs than ECT preferrers. sciencedirect.com/science/articl…

Cardiology study looking at people who use psychedelics a colleague is working on, please share, requires in person visit (Boston).

Great news for patients and psychiatric providers—the FDA is ending the clozapine REMS! Hopefully this will lead to increased prescribing of this incredible and often lifesaving medication. psychiatrictimes.com/view/fda-offic…

We just responded to a Request for Information from the Congressional PATH Caucus about how to safely and effectively expand patient access to prescription psychedelic medicine. bit.ly/3Xv0ORg

We explored online accounts discussing psychedelic use in people with anosmia. Of those reporting improved ability to smell, ~40% had benefits persisting at least one day post-psychedelic use. pubmed.ncbi.nlm.nih.gov/40022524/

J&J ends phase 3 aticaprant program for depression. Combined with the recent failure of Neumora’s navacaprant for this indication, seems like this could be the end of the line for developing kappa opioid antagonists for depression. fiercebiotech.com/biotech/jj-fai…

Had a great time at Association for Prescription Psychedelics Congressional reception last night. Association for Prescription Psychedelics is advancing federal funding for psychedelic research and patient access post-FDA approval. Peter Hendricks & Fred Barrett will brief Congressional PATH Caucus today.

Intriguing findings from our group's analysis of online accounts of using psilocybin for treating neuropsychiatric long COVID symptoms tandfonline.com/doi/full/10.10…

We joined Buddy Carter for a deep discussion about prescription psychedelics and how the U.S. FDA approval pathway for these therapies will provide American patients in need with safe, effective, and accessible treatments for a wide array of mental health conditions.

Psychedelics for opioid use disorder? Hopefully this paper answers the questions you may have about the current evidence in human clinical studies: sciencedirect.com/science/articl…

Cardiology study recruiting people who use psychedelics—please share, requires in person visit (Boston).

This project grew out of a conversation Andy Francis and I had about lack of data on catatonia’s dynamic nature. We found catatonic signs can appear, disappear and reappear or even change laterality in 24 hours. Catatonic caseness can also come and go. journals.sagepub.com/doi/10.1177/10…

Did a podcast with David Puder M.D. and his team, it was a blast! Check it out if you’re interested in pediatric catatonia or catatonia in autism! podcasts.apple.com/us/podcast/243…

Catatonia & Autism with world class expert Joshua Ryan Smith, MD. Tell me: 1) Something you learned 2) A question for Joshua Ryan Smith, MD 3) Your experience of seeing/treating catatonia

Our study found that while LSD remains widely perceived as difficult to obtain in the US, there was a small increase in perceived availability during the study period, with a notable increase among bisexual respondents and decrease among Black respondents. liebertpub.com/doi/10.1089/ps…

In our survey of psychiatry residents, 83% saw therapeutic promise in psychedelics, but most reported little formal training. ~40% said psychedelic-related opportunities influenced their program ranking or career choice. Training is lagging behind interest tandfonline.com/doi/full/10.10…

Rapid MAOI switches: often feared but rarely studied due to declining MAOI use. We report 3 cases where rapid switches were performed safely. Clinically relevant due to unexpected need for rapid switches caused by intermittent worldwide MAOI shortages. pubmed.ncbi.nlm.nih.gov/40679804/